Blood metabolomics as a next-generation cancer diagnostic platform technology

血液代谢组学作为下一代癌症诊断平台技术

• 批准号: 10067218
• 金额: $ 163.32万
• 依托单位: OXOMICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10067218
• 关键词: Blood; metabolomics; next; generation; cancer

Early diagnosis of cancer improves patient outcomes and saves lives. Unfortunately, a lot of cancers are currently diagnosed late, at stages where treatment options are limited. One underlying cause of this problem is imperfect prescription of routine imaging technologies like CT scanning and MRI, both of which are commonly used for cancer diagnosis. Currently, almost all cancers are diagnosed by observing a symptomatic patient with imaging, but doctors are working with incomplete supporting information and a requirement to make imperfect calls about when to image patients and what imaging results indicate, if anything at all. Apart from poorer patient outcomes, the current approach is both costly and wasteful for the healthcare system while also being stressful for patients and their families.Oxomics technology diagnoses cancer using a simple, universal blood test, coupled with machine learning which identifies cancer-specific patterns of small molecules in the blood called metabolites. Our test fits into existing patient care pathways and offers rapid earlier diagnoses, allowing referral of the right patients for the right imaging at the right time, improving patient outcomes. We have already shown that our technology can be used to accurately find cancer in an under-served population of patients with nonspecific symptoms, including cases where we found cancers before they were visible by imaging.The goal of this application is to develop our technology further so that it is available as a regulated clinical test that can be used every day by doctors. We will do this by developing the underlying classification software, building clinical evidence in specific key cancers and working with regulators to ensure quality and reproducibility from our tests.

癌症的早期诊断改善了患者的预后，挽救了生命。不幸的是，目前许多癌症的诊断都很晚，处于治疗选择有限的阶段。这个问题的一个根本原因是没有完善的常规成像技术，如CT扫描和MRI，这两种技术都通常用于癌症诊断。目前，几乎所有的癌症都是通过观察有症状的患者进行成像来诊断的，但医生的支持信息不完整，而且要求打出不完美的电话，说明何时对患者进行成像，以及成像结果表明了什么，如果有的话。除了患者预后较差外，目前的方法对医疗系统来说既昂贵又浪费，同时对患者及其家人也有压力。氧组学技术使用简单、通用的血液测试和机器学习来诊断癌症，机器学习识别血液中称为代谢物的小分子的癌症特异性模式。我们的测试适合现有的患者护理路径，并提供快速的早期诊断，允许在正确的时间转介正确的患者进行正确的成像，从而改善患者的预后。我们已经证明，我们的技术可以用来在服务不足的具有非特异性症状的患者群体中准确地发现癌症，包括我们在通过成像可以看到癌症之前发现癌症的病例。这项应用的目标是进一步发展我们的技术，使其作为一种受监管的临床测试可供医生每天使用。我们将通过开发基本的分类软件，建立特定关键癌症的临床证据，并与监管机构合作，确保我们测试的质量和重复性，从而做到这一点。